Conference Coverage

October 20, 2017

Payers can predict budget implications of high-cost drugs in the pipeline

A University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.

Meeting the 'status quo' with CMS Star Ratings equals regression

CMS' 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.

Payers need access to pre-approval drug information

Pre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.